FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Walewski

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Anna Czyz; Dominik Dytfeld; Lidia Gil; Andrzej Hellmann; Wanda Knopinska-Posluszny; Anna Lojko-Dankowska; Adam Nowicki; Joanna Romejko-Jarosinska; Jan Walewski; Mieczyslaw Komarnicki
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Fie Juhl Vojdeman; Jan Walewski; Marinus van Oers; Mars van't Veer; Maija Itälä-Remes; Jesper Jurlander; Eva Kimby; Nikolai Kirkby; Tomas Kozák; Michela Montagna; Aaron Polliack; Mario Regazzi; Geir Erland Tjønnfjord; Christian Hartmann Geisler
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
Sergiusz Markowicz; Aleksandra Misicka; Zbigniew I Nowecki; Hanna Polowniak-Pracka; Piotr Rutkowski; Henryk Skurzak; Tomasz Switaj; Marzena Biernacka; Anna Jakubowska-Mucka; Andrzej W Lipkowski; Jan Walewski
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Walewski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anna Czyz; Dominik Dytfeld; Lidia Gil; Andrzej Hellmann; Wanda Knopinska-Posluszny; Anna Lojko-Dankowska; Adam Nowicki; Joanna Romejko-Jarosinska; Jan Walewski; Mieczyslaw Komarnicki
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Leukemia & lymphoma 2013;54(5):973-8.
2013: Fie Juhl Vojdeman; Jan Walewski; Marinus van Oers; Mars van't Veer; Maija Itälä-Remes; Jesper Jurlander; Eva Kimby; Nikolai Kirkby; Tomas Kozák; Michela Montagna; Aaron Polliack; Mario Regazzi; Geir Erland Tjønnfjord; Christian Hartmann Geisler
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
Leukemia & lymphoma 2013;54(4):790-3.
2012: Sergiusz Markowicz; Aleksandra Misicka; Zbigniew I Nowecki; Hanna Polowniak-Pracka; Piotr Rutkowski; Henryk Skurzak; Tomasz Switaj; Marzena Biernacka; Anna Jakubowska-Mucka; Andrzej W Lipkowski; Jan Walewski
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.
Medical oncology (Northwood, London, England) 2012;29(4):2966-77.
2012: Maria Kowalska; Malgorzata Syczewska; Joanna Tajer; Jan Walewski; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Janina Kaminska
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(5):1733-8.
2012: Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Janina Kaminska; Beata Kotowicz; Jan Walewski
Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.
Medical oncology (Northwood, London, England) 2012;29(3):2143-7.
2012: Pier Luigi Zinzani; Rena Buckstein; Dolores Caballero; Yusri A Elsayed; Christopher Enny; Dixie-Lee Esseltine; Bernardo Garicochea; Nuriet K Khuageva; Pierre Soubeyran; Panteli Theocharous; Achiel Van Hoof; Jan Walewski; Huaqing Wang; Eugene Zhu; Bertrand Coiffier
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Journal of hematology & oncology 2012;5():67.
2011: Andrzej Hellmann; Huaibao Feng; Suzette Girgis; Hamina Patel; Simon Rule; Ofer Shpilberg; Donna M Skee; Helgi van de Velde; Jan Walewski; Vernon Louw
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Clinical pharmacokinetics 2011;50(12):781-91.
2011: Martin Dreyling; Steven Le Gouill; Elena Hartmann; Olivier Hermine; Georg Hess; Eva Hoster; Grit Hutter; Hanneke C Kluin-Nelemans; Patricia Perez-Galan; Christiane Pott; Vincent Ribrag; Gael Roue; Simon Rule; Itziar Salaverria; Michal Szymczyk; Michael Unterhalt; Umberto Vitolo; Jan Walewski; Francesco Zaja; Sílvia Beà; Sergio Cortelazzo
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
Leukemia & lymphoma 2011;52(12):2226-36.
2011: Barbara Pienkowska-Grela; Grzegorz Rymkiewicz; Katarzyna Czyz-Domanska; Beata Grygalewicz; Paulina Krawczyk; Renata Woroniecka; Jan Walewski
Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.
Medical oncology (Northwood, London, England) 2011;28(4):1589-95.
2011: Michael Pfreundschuh; Viola Poeschel; Lois Shepherd; Ofer Shpilberg; Rolf Stahel; Marek Trneny; Lorenz Trümper; Jan Walewski; Pier Luigi Zinzani; Peter de Nully Brown; Devinder S Gill; Sandra Grass; Ulrich Jaeger; Evelyn Kuhnt; Stein Kvaloy; Markus Loeffler; Armando López-Guillermo; Noel Milpied; Niels Murawski; Anders Osterborg; Ruth Pettengell
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
The lancet oncology 2011;12(11):1013-22.
2011: Bertrand Coiffier; Michael Crump; Sven de Vos; Yusri A Elsayed; Christopher Enny; Dixie Esseltine; Xiaonan Hong; Jiri Mayer; Fritz Offner; Evgenii A Osmanov; Simon Rule; Adriana Scheliga; Ofer Shpilberg; Adriana Teixeira; Panteli Theocharous; Helgi van de Velde; Jan Walewski; Eugene Zhu; Pier Luigi Zinzani
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
The lancet oncology 2011;12(8):773-84.
2011: Maria Kowalska; Janina Kaminska; Malgorzata Fuksiewicz; Beata Kotowicz; Magdalena Chechlinska; Agnieszka Druzd-Sitek; Jan Walewski
A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival.
Medical oncology (Northwood, London, England) 2011;28(1):194-8.
2011: Matti S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; Ruth Pettengell; Vivianne C G Tjan-Heijnen; Jan Walewski; Damien C Weber; C Zielinski
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
European journal of cancer (Oxford, England : 1990) 2011;47(1):8-32.
2010: Bertrand Coiffier; Nedjad Losic; Birgitte Biilmann Rønn; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Frederiksen; Marinus H J van Oers; James E Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Tadeusz Robak; Jørgen Petersen
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.
British journal of haematology 2010;150(1):58-71.
2010: Jan Walewski; Elzbieta Lampka; Joanna Tajer; Włodzimierz Osiadacz; Ewa Kraszewska; Jolanta B Krzyzanowska; Janusz Meder
CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study.
Medical oncology (Northwood, London, England) 2010;27(2):262-7.
2010: Maria Kowalska; Agnieszka Druzd-Sitek; Malgorzata Fuksiewicz; Beata Kotowicz; Magdalena Chechlinska; Malgorzata Syczewska; Jan Walewski; Janina Kaminska
Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
Clinical biochemistry 2010;43(6):604-8.
2009: Ruth Pettengell; Matti Aapro; Ercole Brusamolino; Dolores Caballero; Bertrand Coiffier; Michael Pfreundschuh; Marek Trneny; Jan Walewski
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
Clinical drug investigation 2009;29(8):491-513.
2009: E Paszkiewicz-Kozik; J Kulik; A Fabisiewicz; A Tysarowski; Ewa Kraszewska; Janusz A Siedlecki; Jan Walewski
Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma.
Medical oncology (Northwood, London, England) 2009;26(1):16-21.
2008: Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Blood 2008;112(6):2248-60.
2008: Ewa Kalinka-Warzocha; Jaroslaw Wajs; Ewa Lech-Maranda; Bernadetta Ceglarek; Jerzy Holowiecki; Irena Federowicz; Jan Walewski; Jaroslaw Czyz; Tadeusz Robak; Krzysztof Warzocha
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Cancer 2008;113(2):367-75.
2008: Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood 2008;111(12):5486-95.
2008: Michael Pfreundschuh; Anthony Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
The lancet oncology 2008;9(5):435-44.
2008: Bertrand Coiffier; Stéphane Lepretre; Lars Møller Pedersen; Ole Gadeberg; Henrik Fredriksen; Marinus H J van Oers; James E Wooldridge; Janusz Kloczko; Jerzy Holowiecki; Andrzej Hellmann; Jan Walewski; Mimi Flensburg; Jørgen Petersen; Tadeusz Robak
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Blood 2008;111(3):1094-100.
2007: B Nasilowska-Adamska; P Rzepecki; J Manko; A Czyz; M Markiewicz; I Federowicz; Agnieszka Tomaszewska; Beata Piatkowska-Jakubas; Agata Wrzesien-Kus; Maria Bieniaszewska; D Duda; Richard Szydlo; Kazimierz Halaburda; A Szczepinski; A Lange; A Hellman; Tadeusz Robak; Aleksander B Skotnicki; Wieslaw Wiktor Jedrzejczak; Jan Walewski; Jerzy Holowiecki; Mieczyslaw Komarnicki; Anna Dmoszynska; Krzysztof Warzocha; Bozena Marianska
The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Bone marrow transplantation 2007;40(10):983-8.
2007: Piotr Centkowski; Lidia B Brydak; Magdalena Machała; Ewa Kalinka-Warzocha; Maria Błasińska-Morawiec; Irena Federowicz; Jan Walewski; Joanna Wegrzyn; Dariusz Wołowiec; Ewa Lech-Marańda; Joanna Sawczuk-Chabin; Przemysław Biliński; Krzysztof Warzocha
Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
Journal of clinical immunology 2007;27(3):339-46.
2007: Jaroslaw Czyz; Rafal Dziadziuszko; W Knopinska-Posłuszny; Andrzej Hellmann; Lucja Kachel; J Hołowiecki; A Czyz; Mieczyslaw Komarnicki; M Osowiecki; Jan Walewski; Wojciech Jurczak; Aleksander B Skotnicki
Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: analysis of prognostic factors and comparison with a single procedure.
Leukemia & lymphoma 2007;48(3):535-41.
2007: Andrzej Tysarowski; Anna Fabisiewicz; Ewa Paszkiewicz-Kozik; Jadwiga Kulik; Jan Walewski; Janusz A Siedlecki
Usefulness of real-time PCR in long-term follow-up of follicular lymphoma patients.
Acta biochimica Polonica 2007;54(1):135-42.
2006: Matti S Aapro; D A Cameron; Ruth Pettengell; J Bohlius; Jeffrey Crawford; M Ellis; N Kearney; G H Lyman; Vivianne C G Tjan-Heijnen; Jan Walewski; D C Weber; C Zielinski
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
European journal of cancer (Oxford, England : 1990) 2006;42(15):2433-53.
2006: Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noël Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
The lancet oncology 2006;7(5):379-91.
2006: Grzegorz Rymkiewicz; Konrad Ptaszyński; Jan Walewski; Katarzyna Błachnio; Pawel Swoboda; Monika Gos; Ewa Paszkiewicz-Kozik; Renata Woroniecka; Barbara Pieńkowska-Grela; Małgorzata Czarnocka; Przemyslaw Janik
Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.
Medical oncology (Northwood, London, England) 2006;23(3):423-8.
2006: Grzegorz Rymkiewicz; Ewa Paszkiewicz-Kozik; Katarzyna Blachnio; Anna Pastwiska; Jadwiga Kulik; Barbara Pienkowska-Grela; Jan Walewski
Unusual IgD+/CD38-follicular lymphoma with leukemic presentation.
Medical oncology (Northwood, London, England) 2006;23(1):131-5.
2006: Agnieszka Gajkowska; Tomasz Oldak; Marzena Jastrzewska; Eugeniusz K Machaj; Jan Walewski; Ewa Kraszewska; Zygmunt Pojda
Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells in leukapheresis product and bone marrow for clinical transplantation: a comparison of three methods.
Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2006;44(1):53-60.
2005: Peter WM Johnson; John A Radford; Michael H Cullen; Matthew R Sydes; Jan Walewski; Andrew S Jack; Kenneth A MacLennan; Sally P Stenning; Simon Clawson; Paul Smith; David Ryder; Barry W Hancock
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9208-18.
2005: Robert Marcus; Kevin Imrie; Andrew R Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.
Blood 2005;105(4):1417-23.
2005: Barbara Pienkowska-Grela; Anna Witkowska; Beata Grygalewicz; Grzegorz Rymkiewicz; Jolanta Rygier; Renata Woroniecka; Jan Walewski
Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.
Cancer genetics and cytogenetics 2005;156(2):114-21.
2005: Grzegorz Rymkiewicz; Monika Gos; Katarzyna Błachnio; Renata Woroniecka; Pawel Swoboda; Barbara Pieńkowska-Grela; Marika Kulińska; Anna Borawska; Przemyslaw Janik; Jan Walewski
Mantle cell lymphoma presenting with paraproteinemia.
Medical oncology (Northwood, London, England) 2005;22(3):319-23.
2004: Jaroslaw Czyz; Rafal Dziadziuszko; W Knopinska-Postuszuy; Andrzej Hellmann; Lucja Kachel; Jerzy Holowiecki; J Gozdzik; Janusz Hansz; A Avigdor; A Nagler; M Osowiecki; Jan Walewski; Patrycja Mensah; Wojciech Jurczak; Aleksander B Skotnicki; M Sedzimirska; Andrzej Lange; Wieslaw Sawicki; Kazimierz Sulek; Malgorzata Wach; Anna Dmoszynska; A Kus; Tadeusz Robak; Krzysztof Warzocha
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1222-30.
2004: Jaroslaw Czyz; Richard Szydlo; Wanda Knopinska-Posluszny; Andrzej Hellmann; J Gozdzik; Janusz Hansz; P Smolewski; Tadeusz Robak; M Osowiecki; Jan Walewski; A Avigdor; A Nagler; T Zemelka; Marek Pawlicki; Z Sawicki; M Wojtukiewicz; Lucja Kachel; Jerzy Holowiecki; G Charlinski; Wieslaw Wiktor Jedrzejczak
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.
Bone marrow transplantation 2004;33(12):1225-9.
2004: Nicola Gökbuget; Renato Bassan; Adriaan Dekker; Hervé Dombret; Robin Foà; Norbert Ifrah; Tibor J Kovacsovics; Boris Labar; Franco Mandelli; Giovanna Meloni; Joseph Maria Ribera; Bengt Smedmyr; Jean-Paul Vernant; Jan Walewski; Rein Willemze; Dieter Hoelzer
Developing a European network for adult ALL.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5 Suppl 3():S46-52.
2003: Jerzy Hołowiecki; Sebastian Giebel; Jan Walewski; Małgorzata Krawczyk-Kuliś; Andrzej Hellmann; Aleksander B Skotnicki; Anna Dmoszyńska; Joanna Romejko; Jaroslaw Czyz; Wojciech Jurczak; Łucja Kachel; Jerzy Wojnar; Beata Stella-Hołowiecka; Maria Saduś-Wojciechowska; Kazimierz Sułek; Wieslaw Wiktor Jedrzejczak; Tadeusz Robak; Bozena Mariańska; Cezary Szczylik; Krzysztof Warzocha
[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group].
Polskie Archiwum Medycyny Wewnętrznej 2003;110(2):863-8.
2002: Graham M Mead; Matthew R Sydes; Jan Walewski; Andrew Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; JJ McKendrick; Sally P Stenning; D Wright; P Norbert
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1264-74.
2002: Jaroslaw Czyz; Andrzej Hellmann; Rafal Dziadziuszko; Janusz Hansz; J Goździk; J Hołowiecki; B Stella-Hołowiecka; Ł Kachel; W Knopińska-Posłuszny; A Nagler; J Meder; Jan Walewski; E Lampka; K Sułek; Wieslaw Sawicki; Andrzej Lange; K Forgacz; Krzysztof Suchnicki; T Pacuszko; Aleksander B Skotnicki; Patrycja Mensah; Wojciech Jurczak; Kazimierz Kuliczkowski; Tomasz Wróbel; G Mazur; A Dmoszyńska; Malgorzata Wach; Tadeusz Robak; Krzysztof Warzocha
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Bone marrow transplantation 2002;30(1):29-34.
2002: Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski
Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
Blood 2002;99(12):4379-85.
2002: Sergiusz Markowicz; Jan Walewski; K Zajda; P J Wiechno; Henryk Skurzak; J Giermek; Agnieszka Gajkowska; Maciej Krzakowski; Tadeuz Pienkowski
Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy.
Cytokines, cellular & molecular therapy 2002;7(1):15-24.
2001: Jan Walewski; Ewa Kraszewska; O Mioduszewska; J Romejko-Jarosińska; Andrzej Hellmann; Jaroslaw Czyz; J Hołowiecki; Malgorzata Kopera; Sebastian Grosicki; Mieczyslaw Komarnicki; L Rumianowski; K Kuliczkowski; Tomasz Wróbel; Jadwiga Dwilewicz - Trojaczek; Tadeusz Robak; Krzysztof Warzocha; J Załuski; E Wójcik; A Dmoszyńska; Adam Walter-Croneck
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Medical oncology (Northwood, London, England) 2001;18(2):141-8.
2001: Sergiusz Markowicz; Henryk Skurzak; Jan Walewski
A method for directly determining the number of dendritic cells and for evaluation of their function in small amounts of human peripheral blood.
Archivum immunologiae et therapiae experimentalis 2001;49(1):51-7.
2000: Jan Walewski; J B Krzyzanowska; Ewa Kraszewska; E Lampka; J Romejko-Jarosińska; Z Miśkiewicz; J Meder
CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Medical oncology (Northwood, London, England) 2000;17(3):195-202.
1999: L Poplawska-Szczyglowska; Jan Walewski; Barbara Pienkowska-Grela; Grzegorz Rymkiewicz; O Mioduszewska
Chronic lymphocytic leukaemia presenting with central nervous system involvement.
Medical oncology (Northwood, London, England) 1999;16(1):65-8.
1997: T Róbak; Joanna Gora-Tybor; Euzebiusz Krykowski; Jan Walewski; A Borawska; A Pluźańska; Piotr Potemski; Andrzej Hellmann; Jan M Zaucha; Lech Konopka; Bernadetta Ceglarek; T Durźyński; Anna Sikorska; K Michalak; J Urasiński; J Opalińska; A Dmoszyńska; Maria Adamczyk-Cioch; Z Kuratowska; Jadwiga Dwilewicz - Trojaczek; Piotr Boguradzki; M Deren; Stanislaw Maj; P Grieb
Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;26(1-2):99-105.